Aceruloplasminemia is a very rare inherited condition in which the body cannot move and handle iron normally because it has little or no working ceruloplasmin, a protein that helps process iron. Iron then builds up in the brain and other organs. Over time, this can cause anemia, diabetes, changes in the retina, and problems with movement, balance, or thinking. Symptoms usually begin in adulthood.
How Does Aceruloplasminemia Affect the Body?
Aceruloplasminemia is a genetic disorder of iron metabolism, the process that controls how the body uses and transports iron. Iron is essential for making hemoglobin, the protein in red blood cells that carries oxygen. However, the body must also move and regulate iron properly to prevent it from collecting in tissues where it can cause damage.
Ceruloplasmin is a protein that helps transport iron out of tissues and prepares it for transport in the blood. When ceruloplasmin is missing or does not work properly, iron handling becomes impaired. Iron can gradually accumulate in organs, including the brain, liver, pancreas, and eyes, while the amount of iron circulating in the blood may be low. According to the U.S. National Library of Medicine's MedlinePlus Genetics, this buildup can damage cells and contribute to neurological and other health problems.
The condition is also classified as a form of neurodegeneration with brain iron accumulation, a group of rare disorders in which excess iron collects in the brain and may interfere with nervous system function.
What Causes Aceruloplasminemia?
Aceruloplasminemia results from disease-causing changes in the CP gene. This gene provides instructions for making ceruloplasmin. When both copies of the gene have disease-causing changes, the body may produce an unstable or nonfunctional protein, or it may be unable to release the protein properly from cells.
The condition follows an autosomal recessive inheritance pattern. This means an affected person generally inherits one disease-causing CP gene variant from each biological parent. Parents who carry one altered copy usually do not develop the condition themselves.
When both parents are carriers, each pregnancy has a 25% chance of resulting in a child with aceruloplasminemia, a 50% chance of resulting in a child who is a carrier, and a 25% chance of resulting in a child who inherits neither disease-causing variant. These probabilities apply independently to each pregnancy. The National Organization for Rare Disorders (NORD) describes this inheritance pattern and notes that the condition can affect different members of the same family differently.
What Symptoms Can Aceruloplasminemia Cause?
Symptoms usually become noticeable during adulthood, although the age at which they appear and the order in which they develop can differ. Some people first have blood abnormalities, while others are identified after developing diabetes, eye changes, or neurological symptoms.
Possible features include the following:
- Anemia: Reduced availability of iron for red blood cell production can lead to anemia. This may be associated with tiredness, weakness, or reduced stamina.
- Diabetes mellitus: Iron accumulation in the pancreas may damage the cells that produce insulin, affecting blood glucose control.
- Retinal changes: Excess iron may cause changes in the retina, the light-sensitive tissue at the back of the eye. These changes may be detected during an eye examination even when vision is not noticeably affected.
- Movement difficulties: Iron accumulation in particular brain regions may contribute to tremors, involuntary muscle contractions, unusual facial movements, or difficulty coordinating movements and walking.
- Changes in thinking or behavior: Some affected people develop problems with memory, thinking, mood, or other aspects of mental function as the condition progresses.
According to the NIH Genetic and Rare Diseases Information Center (GARD), neurological problems may include tremors, difficulty coordinating movements, involuntary movements, and cognitive changes. These features are not unique to aceruloplasminemia, so their significance depends on the person's medical history, examination, and test results.
How Is Aceruloplasminemia Diagnosed?
Diagnosis usually involves combining blood tests, clinical findings, brain imaging, and genetic testing. Because the condition is rare, it may be considered when otherwise unexplained anemia or an unusual pattern of iron-related blood results occurs alongside diabetes, retinal changes, or neurological difficulties.
Blood tests
Blood tests may show very low or absent ceruloplasmin, low serum copper, low serum iron, and elevated ferritin. Ferritin is a protein that stores iron and is also measured as a marker of the body's iron stores. In aceruloplasminemia, ferritin can be higher than expected even when circulating iron is low, because iron is accumulating in tissues rather than being handled normally.
A complete blood count can help identify anemia, while blood glucose testing can assess for diabetes. Liver-related tests and other investigations may be used to assess organ involvement. Individual results need to be interpreted together because no single blood test is sufficient to establish the diagnosis.
Brain imaging and eye examinations
Magnetic resonance imaging (MRI) of the brain can help identify abnormal iron accumulation in certain brain regions. An eye specialist may examine the retina for characteristic changes. Additional tests may be appropriate when clinicians need to assess the liver, pancreas, or other potentially affected organs.
Genetic testing
Genetic testing can identify disease-causing variants in both copies of the CP gene. According to GeneReviews, published by the U.S. National Library of Medicine, a diagnosis is established by finding the characteristic clinical and laboratory features together with disease-causing variants in both copies of the gene.
Genetic counseling may help affected individuals and their relatives understand the inheritance pattern, the implications of test results, and whether family members may benefit from genetic testing.
How Is Aceruloplasminemia Managed?
Management is individualized and generally involves specialists familiar with rare metabolic, neurological, and genetic conditions. The aims are to address existing health problems, monitor for complications, and consider whether reducing excess iron may help limit further tissue damage.
Iron-chelating medicines bind to excess iron so that the body can remove it. Medicines such as deferiprone, deferoxamine, or deferasirox have been used in affected individuals. However, evidence about how well iron chelation prevents or reverses neurological problems remains limited. The potential benefits and risks must be assessed by specialists rather than assuming that lowering iron measurements will necessarily improve every symptom.
Blood removal, known as phlebotomy, has also been used in selected treatment approaches, sometimes alongside iron chelation. Because people with aceruloplasminemia may already have anemia, removing blood can create additional risks and is not appropriate for everyone. NORD describes these treatment approaches while emphasizing the uncertainty surrounding their effects on neurological progression.
Care may also include treatment for diabetes, assessment of vision, support for movement and coordination difficulties, and help with cognitive or psychological changes when needed. Follow-up commonly includes blood counts, glucose assessment, liver function testing, and review of neurological and eye findings. The schedule depends on the person's health and the recommendations of their care team.
What Is the Outlook for Someone With Aceruloplasminemia?
The outlook varies according to which organs are affected, when the condition is recognized, and how it progresses. Neurological problems can become more noticeable over time, but the pattern and rate of change are not the same for everyone. Some complications, such as diabetes or anemia, may require ongoing management even when other symptoms are limited.
Recognizing the condition can help clinicians organize appropriate monitoring and care. Persistent unexplained anemia, particularly when accompanied by unusual iron-related blood results, diabetes, retinal changes, or movement difficulties, should be discussed with a healthcare professional. These findings have many possible explanations, and assessment is needed to determine whether they are related to one another.